BRKRBruker Corporation
Is the price fair?
A demanding price: priced for +27% a year vs +9% a year delivered and at the top of its own P/E range.
Priced for ~27% a year FCF growth. The price demands more than its three-year revenue growth of 9% a year, priced for acceleration.
Expensive vs its own history: P/E 78.8 vs a 34.2 median over 37 quarters (+130% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BRKR's price assumes
Today's price asks for 27% free cash flow growth a year; over the last three years Bruker Corporation delivered −22%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.0%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +27%
Growth the price implies · The price pays for +27% free cash flow growth a year for a decade; the business has delivered −22% a year over the last three.
- Price / book
- 3.86
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.86
- EV / EBIToperating margin −0.87%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.12
- Free cash flow, trailing twelve months
- $94M
- Market capitalisation
- $9.27B
- 3-year revenue growth
- +8.8%
- 3-year free cash flow growth
- −22%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.